One of the oldest treatment options in rheumatology, colchicine, may be an effective and inexpensive treatment to prevent complications in non-hospitalized patients with COVID-19, particularly in men, according to the results of large global study.
![](https://www.the-rheumatologist.org/wp-content/uploads/2018/12/iStock.com_monsitj_GenericTechnology_500x270-150x150.jpg)
One of the oldest treatment options in rheumatology, colchicine, may be an effective and inexpensive treatment to prevent complications in non-hospitalized patients with COVID-19, particularly in men, according to the results of large global study.
Ibrahem Salloum, MD, & Deepan S. Dalal, MD, MPH |
Discovered more than 3,000 years ago, colchicine is one of the oldest drugs still in use today. Like most old remedies, colchicine is a chemical substance found in many plants, most notably in colchicum autumnale, known as wild saffron or autumn crocus. It was mentioned in the oldest Egyptian medical text, Ebers Papyrus (circa 1550…
The FDA has issued a boxed warning for febuxostat after a safety study found an increased risk of heart-related and other death in RA patients…
The cost for therapeautic gout treatment may soon go down, thanks to a recent court ruling
Drug’s antiinflammatory properties may help alleviate pain in patients with OA, reduce risk of myocardial infarction, but toxicity, drug interactions need to be considered
Gurjit S. Kaeley, MRCP |
A rheumatologist warns against generalizing findings of the study reported in “Colchine Effective for Acute Pericarditis” [published online October 31, 2013] to all patients with rheumatic diseases
Patients with acute pericarditis who are treated with colchicine in combination with a traditional antiinflammatory therapy experience a significantly reduced rate of incessant or recurrent pericarditis. (posted Oct. 31)
Experts from across the nation describe the best clinical approaches to rheumatologic disease management.
Some rheumatologists question the depth of research and the approval’s implications for patient access
Stanley B. Cohen, MD |
A program to improve drug safety has increased drug prices for patients with gout and FMF